Table 3. Characteristics of the AIH-related autoantibodies positive and negative AHE patients.
| Variable | AIH-related autoantibodies positive group (n = 99) | AIH-related autoantibodies negative group (n = 99) | P | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | ||||
| Age (y) | 55.21 ± 11.52 | 56.18 ± 12.47 | 0.102 | 1.00 (0.98–1.05) | 0.891 | ||
| Females | 66.7% (66/99) | 45.5% (45/99) | 0.021 | 0.94 (0.39–4.22) | <0.001 | 1.02 (0.42–5.44) | 0.003 |
| WBC (109/L) | 6.42 (5.51–8.88) | 6.21 (5.64–8.87) | 0.443 | 2.27 (0.96–5.25) | 0.879 | ||
| RBC (1012/L) | 4.18 ± 0.65 | 4.09 ± 0.61 | 0.551 | 1.09 (0.81–1.34) | 0.477 | ||
| ALT (U/L) | 592.00 (147.00–1381.00) | 375.00 (104.00–915.00) | 0.007 | 0.75 (0.61–0.98) | <0.001 | 0.79 (0.67–1.08) | 0.012 |
| AST (U/L) | 382.00 (95.00–1105.00) | 208.00 (81.00–618.00) | 0.032 | 0.74 (0.62–0.93) | 0.002 | ||
| GGT (U/L) | 99.00 (57.50–172.00) | 98.00 (57.00–175.50) | 0.513 | 0.46 (0.29–0.79) | 0.533 | ||
| TP (g/L) | 57.54 ± 8.25 | 56.56 ± 9.16 | 0.659 | 0.97 (0.94–1.01) | 0.285 | ||
| ALB (g/L) | 31.59 ± 5.62 | 31.31 ± 5.67 | 0.978 | 0.95 (0.88–0.97) | 0.068 | ||
| UREA (mmol/L) | 4.56 (3.50–6.97) | 4.62 (3.78–7.02) | 0.553 | 2.10 (1.35–4.64) | 0.098 | ||
| CR (umol/L) | 76.43 (66.50–93.00) | 76.00 (65.50–93.50) | 0.550 | 1.69 (0.79–3.71) | 0.170 | ||
| PT (s) | 17.39 (15.03–23.12) | 17.47 (14.95–22.19) | 0.679 | 5.71 (2.65–19.76) | 0.096 | ||
| INR | 1.97 (1.92–2.29) | 1.51 (1.22–2.02) | 0.043 | 6.94 (2.55–16.18) | 0.009 | ||
| PLT (109/L) | 136.00 (90.50–169.00) | 139.00 (92.00–172.50) | 0.553 | 0.52 (0.27–0.89) | 0.059 | ||
| CRP (mg/L) | 10.99 (7.15–14.25) | 9.56 (7.03–13.89) | 0.986 | 0.98 (0.97–1.16) | 0.977 | ||
| TBIL (umol/L) | 296.27 ± 163.12 | 290.17 ± 155.42 | 0.932 | 1.01 (1.00–1.01) | 0.014 | ||
| AFP (ng/ml) | 35.41 (7.20–115.00) | 38.10 (6.90–122.20) | 0.905 | 0.99 (0.81–1.23) | 0.953 | ||
| CHE (U/L) | 2795.80 (2353.60–3155.80) | 2688.80 (2418.35–3212.77) | 0.337 | 0.98 (0.22–0.69) | 0.655 | ||
| HEV-IgG | 85.9% (85/99) | 83.8% (83/99) | 0.665 | 1.22 (0.32–0.89) | 0.499 | ||
| Jaundice | 74.7% (74/99) | 67.7% (67/99) | 0.844 | 1.31 (0.35–0.81) | 0.505 | ||
| IgG (mg/dL) | 2.22 ± 0.55 | 1.50 ± 0.41 | 0.028 | 0.68 (0.52–1.88) | 0.005 | ||
| Taking immuno-suppressive drugs | 5.1% (5/99) | 4.0% (4/99) | 0.905 | 1.43 (0.19–0.79) | 0.662 | ||
| Past or current autoimmune diseases | 6.1% (6/99) | 4.0% (4/99) | 0.337 | 1.33 (0.23–0.91) | 0.506 | ||
| Antiviral therapy | 79.8% (79/99) | 72.7% (72/99) | 0.962 | 1.09 (0.36–0.94) | 0.294 | ||
Note: AST, Glutamic oxaloacetic transaminase; ALT, Alanine aminotransferase; AFP, Alpha fetoprotein; WBC, white blood cell; RBC, red blood count; CHE, cholinesterase; UREA, urea nitrogen; CR, creatinine; PT, prothrombin time; TBIL, total bilirubin; ALB, albumin; INR, international normalized ratio; PLT, platelet; CRP, c-reactive protein.